Nashwan Mustafa Sulaiman Al Hafidh
@uoninevah.edu.iq
pediatrics
Ninavah university
EDUCATION
Assistant professor in pediatrics
Department of pediatrics, Ninevah College of medicine, Ninevah University, Mosul city, Iraq.
RESEARCH INTERESTS
pediatrics , celiac disease , thalassemia , nutrition
Scopus Publications
Scholar Citations
Scholar h-index
Scopus Publications
Elham KhAljammas, Muhammed A Ahmed Al Kataan, and Nashwan M Al Hafidh
Bangladesh Academy of Sciences
objective: Iron is the most abundant metal within the mitochondrial matrix . Ferritin reflects bodyironstores. This study aimed to assess the association between serum ferritin levels and mitochondrial function in children. Methods: Two hundred and forty-three children from four governmental primary schools in Mosul city in Iraq were randomly selected by a multistage random sampling method. Their age range was 6-12 years. Mitochondrial function tests involved measurement of serum lactate, serum pyruvate, and L-Carnitine were analyzed in all selected children along with serum ferritin. Results: Lower levels of serum ferritin weresignificantly associated with higher levels of serum lactate, serum lactate/serum pyruvate ratio. There was a significant negative correlation (p = 0.000, - 0.296,- 0.286) between mean serum ferritin level and mean serum lactate, serum lactate / serum pyruvate ratio respectively.There were significant differences (p= 0.000) in mean serum level of mitochondrial function tests (Lactate, L- Carnation, and L/P ratio) in comparing children possessing a normal level of serum ferritin versus those with a low serum ferritin level of < 12 ng/ml. ROC analysis showed that when the area under the curve (AUC) was 0.761 ± SE 0.37, a cut off value 4.79 ng/ml of serum ferritin was significantly (p=0 .000) associated with sensitivity of 100 % and 1- specificity of 0.861 value with presence of L: P molar ratio of ≤ equal 20. Conclusion:Serum ferritin < 12 ng/ ml represntsmitochondrial deficient level. Serum ferritin < 4.79 ng/ml was the critical value at which only 8.6% of children will have a healthy mitochondrial function. Bangladesh Journal of Medical Science Vol. 22 No. 02 April’23 Page : 374-378
Nashwan M. Al-Hafidh, Faris B. Al-sawaf, and Rafida H. Khalaf
Africa Health Research Organization
Many local breast-feeding infants were observed using pacifiers during first month of life. This study aimed to assess the effect of using pacifier during the period of breast-feeding establishment on breast-feeding weaning age.A case control study comparing 131 pacifier users' children during their first month of life versus 173 non-pacifier users in relation to breast feeding weaning age. Each enrolled child was ≥ 6 12 months age and was exclusive breast feeder for at leastthe first month oftheir life.One third (33.6 %) of pacifier user infants had pacifier in their first day of life; Male infant were significantly (p =0.004) more frequent pacifier users than female infants. Infants from extended family structure possessed 11.7 times risk to be a pacifier user (OR: 11.7, CI: 6.747-20.311).Nearly three quarter (71.8%) of pacifier users discontinued breast feeding prior to 6 months of age whereas abouttwo thirds (62.4 %) of pacifier not user maintained on breast feeding beyond age of 6 months (p = 0.000). Using a pacifier carried 4.2 times risk of early weaning from breast-feeding prior to 6 months of age (OR: 4.2, 95% CI 2.59-6.89).Factors that significantly predict early discontinuation of breast-feeding among studied variables were pacifier use, illiterate mother, and extended family structure.Pacifier use in the first month of life must be avoided to support longer than 6 months duration of breast-feeding.
Nashwan M Al Hafidh and Mozahim S Younis
Bangladesh Journals Online (JOL)
Objectives: Abnormal liver function tests lead to interruptions of Deferasirox therapy. The aim of this study is to determine the changes in liver transaminases levels in pediatric patients with β -thalassemia major during one year follow up of Deferasirox treatment.
 Material and methods: This study was conducted at Ibn Al Atheer center of thalassemia, Mosul city, Iraq during the period from 3rd of February 2013 till 2nd of February 2014. Seventy one pediatric patients with β -thalassemia major were included in the study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured every 4 weeks after starting Deferasirox therapy dose of 30 mg /kg/day for one year.
 Results: In comparison to mean baseline ALT values, there were significant elevations of mean ALT values in each of the subsequent 4-weekly interval readingsafter Deferasirox therapy. There was nearly eleven times relative risk of having ALT ≥ 5 upper normal level (UNL) in patient with abnormal baseline ALT (Odd ratio 10.96,95% Confidence Interval: lower 2.05, upper 58.58). During a year of study, Deferasirox therapy was associated withALT readings of ≥ 5UNL in 22(31%) of pediatric β-thalassemia patients and that elevation lasted for 4 weeks in 95.5% of patients.
 Conclusions: Elevated ALT of ≥ 5UNL after Deferasirox therapy was short- lived, and lasted for 4 weeks in 95.5% of patients. It is advisable to start Deferasirox therapy at a dose of 30 mg /kg / day when baseline ALT level is normal.
 Bangladesh Journal of Medical Science Vol.19(3) 2020 p.453-457
Nashwan M Al-Hafidh and Mozahim S. Younis
Dr. Yashwant Research Labs Pvt. Ltd.
Objective: To assess the efficacy of deferasirox median dose of 30 mg /kg /day in pediatric patients with β- thalassemia major during one year of follow up Patients and methods: This study was conducted at Ibn Al Atheer center of thalassemia, Mosul city, Iraq during the period from 3rd of February 2013 to 2nd of February 2014. Serum ferritin was measured at baseline and at four weekly intervals thereafter among 49 transfusion dependent children with β-thalassemia major, who were treated with median deferasirox dose of 30 mg /kg /day. Results: No statistically significant difference was detected between mean serum ferritin level at baseline (2189.39 ± 85.7) ng/mL and its mean value at four weekly intervals during forty-eight weeks of deferasirox therapy. There was significant (p = 0.027) improvement of serum ferritin at fifty – two weeks reading (1750.6 ± 202.8 ng/mL) compared to baseline reading. Percentage of patients with baseline serum ferritin levels of >2,500 ng/ml was 32.7% (16/49), which increased significantly (p=0.000) to 65% at four weeks of therapy, and ranged between 32.1% - 46.2 % in the remaining readings. Conclusions: There was no significant reduction of serum ferritin during initial forty-eight weeks of deferasirox median dose of 30 mg /kg /day among patient with baseline mean serum ferritin above 2000 ng /ml.